73 related articles for article (PubMed ID: 17967304)
1. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
[TBL] [Abstract][Full Text] [Related]
2. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer.
Cheung MR; Tucker SL; Dong L; de Crevoisier R; Lee AK; Frank S; Kudchadker RJ; Thames H; Mohan R; Kuban D
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1059-65. PubMed ID: 17241755
[TBL] [Abstract][Full Text] [Related]
3. An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
Henderson DR; Murray JR; Gulliford SL; Tree AC; Harrington KJ; Van As NJ
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):539-547. PubMed ID: 29807801
[TBL] [Abstract][Full Text] [Related]
4. Impact of Interfractional Bladder and Trigone Displacement and Deformation on Radiation Exposure and Subsequent Acute Genitourinary Toxicity: A Post Hoc Analysis of Patients Treated with Magnetic Resonance Imaging-Guided Prostate Stereotactic Body Radiation Therapy in a Phase 3 Randomized Trial.
Neilsen BK; Ma TM; Akingbemi WO; Neylon J; Casado MC; Sharma S; Sheng K; Ruan D; Low DA; Yang Y; Valle LF; Steinberg ML; Lamb JM; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(4):986-997. PubMed ID: 37871887
[TBL] [Abstract][Full Text] [Related]
5. Defining bowel dose volume constraints for bladder radiotherapy treatment planning.
McDonald F; Waters R; Gulliford S; Hall E; James N; Huddart RA
Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):22-9. PubMed ID: 25445550
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive geriatric assessment predicts radiation-induced acute toxicity in prostate cancer patients.
Paal K; Stranz B; Thurner EM; Langsenlehner U; Renner W; Brunner TB; Langsenlehner T
Strahlenther Onkol; 2024 Mar; 200(3):208-218. PubMed ID: 37658924
[TBL] [Abstract][Full Text] [Related]
7. Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.
Kerns SL; Amidon Morlang A; Lee SM; Peterson DR; Marples B; Zhang H; Bylund K; Rosenzweig D; Hall W; De Ruyck K; Rosenstein BS; Stock RG; Gómez-Caamaño A; Vega A; Sosa-Fajardo P; Taboada-Valladares B; Aguado-Barrera ME; Parker C; Veldeman L; Fonteyne V; Bultijnck R; Talbot CJ; Symonds RP; Johnson K; Rattay T; Webb A; Lambrecht M; de Ruysscher D; Vanneste B; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Rancati T; Avuzzi B; Valdagni R; Azria D; Farcy Jacquet MP; Chang-Claude J; Seibold P; West C; Janelsins M; Chen Y; Messing E; Morrow G;
Radiother Oncol; 2022 Mar; 168():75-82. PubMed ID: 35077710
[TBL] [Abstract][Full Text] [Related]
8. Redefining bladder neck dose in low-dose-rate prostate brachytherapy-Can we improve urinary toxicity without impacting disease control?
Koerner SA; Benoit RM; Beriwal S; Smith RP
Brachytherapy; 2024; 23(1):58-63. PubMed ID: 37821322
[TBL] [Abstract][Full Text] [Related]
9. Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer.
Philipps L; Porta N; James N; Huddart R; Hafeez S; Ballas L; Hall E
Clin Oncol (R Coll Radiol); 2023 May; 35(5):e336-e343. PubMed ID: 36906497
[TBL] [Abstract][Full Text] [Related]
10. Predicting the germline dependence of hematuria risk in prostate cancer radiotherapy patients.
Oh JH; Lee S; Thor M; Rosenstein BS; Tannenbaum A; Kerns S; Deasy JO
Radiother Oncol; 2023 Aug; 185():109723. PubMed ID: 37244355
[TBL] [Abstract][Full Text] [Related]
11. Genitourinary Radiation Injury Following Prostate Cancer Treatment: Assessment of Cost and Health Care System Burden.
Hebert KJ; Matta R; Fendereski K; Horns JJ; Paudel N; Das R; Viers BR; Hotaling J; McCormick BJ; Myers JB
Urology; 2023 Sep; 179():166-173. PubMed ID: 37263424
[TBL] [Abstract][Full Text] [Related]
12. Modeling normal bladder injury after radiation therapy.
Kerns SL; Williams JP; Marples B
Int J Radiat Biol; 2023; 99(7):1046-1054. PubMed ID: 36854008
[TBL] [Abstract][Full Text] [Related]
13. A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort.
Massi MC; Gasperoni F; Ieva F; Paganoni AM; Zunino P; Manzoni A; Franco NR; Veldeman L; Ost P; Fonteyne V; Talbot CJ; Rattay T; Webb A; Symonds PR; Johnson K; Lambrecht M; Haustermans K; De Meerleer G; de Ruysscher D; Vanneste B; Van Limbergen E; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Avuzzi B; Giandini T; Valdagni R; Cicchetti A; Azria D; Jacquet MF; Rosenstein BS; Stock RG; Collado K; Vega A; Aguado-Barrera ME; Calvo P; Dunning AM; Fachal L; Kerns SL; Payne D; Chang-Claude J; Seibold P; West CML; Rancati T
Front Oncol; 2020; 10():541281. PubMed ID: 33178576
[No Abstract] [Full Text] [Related]
14. Delineating the inner bladder surface using uniform contractions from the outer surface under variable bladder filling conditions.
Rosewall T; Bayley A; Catton C; Chung P; Currie G; Heaton R; Wheat J; Milosevic M
Br J Radiol; 2015 Sep; 88(1053):20140818. PubMed ID: 26206519
[TBL] [Abstract][Full Text] [Related]
15. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome.
Jackson A; Marks LB; Bentzen SM; Eisbruch A; Yorke ED; Ten Haken RK; Constine LS; Deasy JO
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3 Suppl):S155-60. PubMed ID: 20171512
[TBL] [Abstract][Full Text] [Related]
16. Bladder Radiotherapy: Is Cinderella Ready for the Ball?
Huddart RA
Clin Oncol (R Coll Radiol); 2021 Jun; 33(6):343-345. PubMed ID: 33895059
[No Abstract] [Full Text] [Related]
17. Spotlight on Bladder and Prostate Cancer and Urinary Retention at Glasgow Gathering: Highlights from the BAUS Annual Meeting June 21-25, 1999, Glasgow, Scotland.
Roehrborn CG
Rev Urol; 2000; 2(2):76-80. PubMed ID: 16985739
[No Abstract] [Full Text] [Related]
18. Dose-volume relationships of planned versus estimated delivered radiation doses to pelvic organs at risk and side effects in patients treated with salvage radiotherapy for recurrent prostate cancer.
Jóhannesson V; Gunnlaugsson A; Nilsson P; Brynolfsson P; Kjellén E; Wieslander E
Tech Innov Patient Support Radiat Oncol; 2024 Mar; 29():100231. PubMed ID: 38192583
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation.
Wang D; Yin Y; Zhou Q; Li Z; Ma X; Yin Y; Li B; Bai T; Li D; Zhu J
Med Phys; 2022 Jan; 49(1):756-767. PubMed ID: 34800297
[TBL] [Abstract][Full Text] [Related]
20. A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer.
Casares-Magaz O; Muren LP; Pettersson N; Thor M; Hopper A; Knopp R; Deasy JO; Væth M; Einck J; Moiseenko V
Phys Imaging Radiat Oncol; 2018 Jul; 7():65-69. PubMed ID: 33458407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
